Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
February 21, 2019 10:45 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained...
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
February 14, 2019 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we...
Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019
January 23, 2019 16:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty...
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of OHR Pharmaceutical, Inc. (OHRP) on Behalf of Stockholders and Encourages OHRP Investors to Contact the Firm
January 04, 2019 18:56 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) on behalf of...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Ohr Pharmaceutical, Inc. to NeuBase Therapeutics, Inc. is Fair to Shareholders
January 04, 2019 12:20 ET
|
Levi & Korsinsky, LLP
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ohr Pharmaceutical, Inc. (“Ohr” or the...
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc.
January 03, 2019 06:30 ET
|
Ohr Pharmaceutical, Inc.
Proposed combined company's peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform enables rapid development of therapies delivered systemically for genetic diseases Initial...
Investor Expectations to Drive Momentum within Ocean Bio-Chem, Gaming Partners International, Pershing Gold, OHA Investment, Ohr Pharmaceuticals, and J. W. Mays — Discovering Underlying Factors of Influence
November 19, 2018 07:20 ET
|
Fundamental Markets
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders,...
Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results
August 14, 2018 16:05 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact The Firm
April 09, 2018 11:23 ET
|
Brower Piven, A Professional Corporation
STEVENSON, Md., April 09, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the...
OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The Firm
March 26, 2018 15:54 ET
|
Faruqi & Faruqi LLP
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (NASDAQ:OHRP) of...